According to our findings, baseline TyG was an independent predictor of HSI remission at three months after LSG in NAFLD patients with obesity, and it is the first time that circulating Prdx1 is proposed as a promising biomarker to assess postoperative improvement of obesity and NAFLD. Here, PRDX1 is linked to metabolic dysfunction-associated steatotic liver disease.